At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 208 enrolled
Drug / intervention
LX3305 low dose +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-center, Randomized, Double Blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy
In Brief
A Phase 2 clinical trial evaluating LX3305 low dose, LX3305 mid dose, and 2 other interventions for Rheumatoid Arthritis. Completed, enrolled 208 participants across 38 sites in 6 countries.
Detailed Summary
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX3305 versus a placebo control in subjects with active rheumatoid arthritis on stable methotrexate therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria, Czechia, Hungary, Poland, Serbia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJul 2009
Primary CompletionSep 2010
TodayJul 2026
First PostedMay 18, 2009
Enrollment StartJul 1, 2009
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.1 years ago
Interventions
LX3305 low dosedrug
A low dose of LX3305; daily oral intake for 12 weeks
LX3305 mid dosedrug
A mid dose of LX3305; daily oral intake for 12 weeks
LX3305 high dosedrug
A high dose of LX3305; daily oral intake for 12 weeks
Placebodrug
Matching placebo dosing with daily oral intake for 12 weeks